Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT01887418

Pharmacokinetic Study of Testosterone Enanthate

3 Arm Open-label Randomized Multidose Study of Pharmacokinetics, Safety & Tolerability of Testosterone Enanthate Administered Subcutaneously Via an Auto-injector Device or Intramuscular Testosterone Enanthate in Hypogonadal Adult Males

Sponsor: Antares Pharma Inc.

Conditions Hypogonadism

Interventions Delatestryl 200 mg IM Treatment C QuickShot™ - 100 mg Treatment A QuickShot™ - 50 mg Treatment B

Updated 6 times since 2017 Last updated: Dec 13, 2017 Started: Sep 30, 2013 Primary completion: Jan 31, 2014 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Hypogonadism, this trial is completed. The trial is conducted by Antares Pharma Inc. and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Antares Pharma Inc.

Data source: Antares Pharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brookline, United States